Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Piroxicam in transitional cell carcinoma of the canine bladder
Transitional cell carcinomas of the urinary bladder sometimes occur especially in older dogs. Often they are nonresecatable. Is piroxicam, a nonsteroidal antiinflammatory drug, a therapy that can be recommended?

Thirty-four dogs with histopathologically confirmed, measurable, nonresectable transitional cell carcinoma of the urinary bladder were treated with piroxicam (0.3 mg/kg PO sid) and were evaluated for tumor response and drug toxicity.

Dogs were evaluated at the Purdue University Veterinary Teaching Hospital by means of physical examination, thoracic and abdominal radiography, cystography, complete blood count, serum biochemistry profile, and urinalysis.
In selected cases, prostaglandin E2 (PGE2) concentrations in plasma and in supernatants of stimulated monocytes, and natural killer cell activity were quantified.

Dogs were evaluated before therapy and at 28 and 56 days after initiation of therapy. Dogs with stable disease or remission at 56 days remained on the study and were evaluated at 1 to 2 months intervals.

Tumor responses were 2 complete remissions, 4 partial remissions, 18 stable diseases, and 10 progressive diseases.

The median survival of all dogs was 181 days (range, 28 to 720+ days), with 2 dogs still alive.

Piroxicam toxicity consisted of gastrointestinal irritation in 6 dogs and renal papillary necrosis (detected at necropsy) in 2 dogs.

Monocyte production of PGE2 appeared to decrease with therapy in dogs whose tumors were decreasing in size, and increased in dogs with tumor progression.

A consistent pattern in natural killer cell activity was not observed. In vitro cytotoxicity assays against 4 canine tumor cell lines revealed no direct antitumor effects of piroxicam.

In summary, antitumor activity, which was not likely the result of a direct cytotoxic effect, was observed in dogs with transitional cell carcinoma of the bladder treated with piroxicam.

Source: Knapp DW, et al (1995): Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. In: J Vet Intern Med. 1995 Mar-Apr;9(2):113-4.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Variability of SDMA in apparently healthy dogsmembers
Symmetric dimethylarginine (SDMA) is a screening tool for early kidney dysfunction and monitoring treatment in cases of chronic kidney disease (CKD). There are no current studies describing the suitability of this test for use with published population‐based reference intervals. The objectives of this study were to determine the components of biological variability, the index of individuality (IOI), the critical difference between sequential measurements (CD) and the number of measurements required to assess the homeostatic set point (HSP), for both SDMA and serum creatinine (sCr), in apparently healthy dogs.

  • Bioavailability of suppository acetaminophen in dogsmembers
  • Computed tomographic lymphography for lymph node staging in dogs with malignant tumors members
  • Characterization of ocular melanosis-affected canine melanocytesmembers
  • Nasopharyngeal sialoceles in brachycephalic dogsmembers
  • Enterococcus faecium SF68 on serum cobalamin and folate concentrationsmembers
  • Gastrointestinal eosinophilic sclerosing fibroplasia limited to the mesentery in a catmembers
  • Ion acid-base disturbances and associated mortality in dogsmembers
  • First description of ultrasonic bone curette in canine otic surgerymembers
  • Staining hair samples with a modified Wright-Giemsa stain to diagnose feline dermatophytosismembers
  • Oral extended release hydrocodone as analgesia after TPLOmembers
  • 25OH vitamin D3 serum concentration in dogs with acute polyradiculoneuritismembers
  • Type 1 immune mediated polyarthritis in dogs and temporal relationship to vaccination members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved